Company
Avyxa Holdings
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
14
14 still marketed
Novel approvals
0
Approvals since 2021
14
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (14)
Newest FDA action first.
- Oxderys Doxorubicin Hydrochloride · 2026
- Axycis Cisplatin · 2026
- Gobarden Bendamustine Hydrochloride · 2025
- Navitrux Fosaprepitant Dimeglumine · 2026
- Favlyxa Fluorouracil · 2026
- Avopef Etoposide · 2026
- Vykoura Leucovorin Calcium · 2026
- Cligavyx Fulvestrant · 2019
- Axtle Pemetrexed Dipotassium · 2024
- Kyxata Carboplatin · 2025
- Frindovyx Cyclophosphamide · 2023
- Avgemsi Gemcitabine Hydrochloride · 2025
- Posfrea Palonosetron Hydrochloride · 2016
- Docetaxel Docetaxel · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.